Plasma nortriptyline and clinical response in depression

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Therapeutics

Background:

• Antidepressant efficacy is often linked to plasma drug concentrations.
• Previous research suggests a therapeutic window for nortriptyline (NT) plasma levels, with levels below 50 ng/ml or above 150 ng/ml potentially yielding suboptimal outcomes.

Purpose of the Study:

• To investigate the clinical efficacy of nortriptyline (NT) in patients with primary, nonbipolar depression when plasma levels fall below the presumed therapeutic threshold.
• To compare the improvement rates in patients with low NT plasma levels to those within the presumed therapeutic range.

Main Methods:

• A randomized controlled trial involving 35 patients with uncomplicated primary, nonbipolar depression.
• Patients received 12 weeks of treatment with either NT alone or NT combined with cognitive therapy.
• Mean NT plasma levels were monitored, with a specific focus on patients with levels below 50 ng/ml.

Main Results:

• Nine out of 35 patients achieved mean NT plasma levels below 50 ng/ml.
• Five of these nine patients showed clinical improvement, reaching a Hamilton Rating Scale for Depression score of less than or equal to 7.
• The improvement rate in patients with NT plasma levels below 50 ng/ml was comparable to that of patients with levels within the presumed therapeutic window.

Conclusions:

• Low plasma levels of nortriptyline (below 50 ng/ml) may not necessarily be associated with inferior clinical outcomes in patients with primary depression.
• The study highlights the need for further investigation into the optimal therapeutic plasma levels for nortriptyline.
• The upper limit of the therapeutic window (150 ng/ml) was not assessed in this study, indicating a gap in current knowledge.